AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04700696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Skill Building based on the Nurturing Parenting Program (NPP)
Description: Home-based parenting support
Study NCT01446965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable defibrillator
Description: LifeVest wearable defibrillator
Study NCT04103333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.
Study NCT03160131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Vision Technology
Description: Training using Neuro Vision Technology
Study NCT03957629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
Study NCT03957629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Interferon alfa 2a
Description: Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
Study NCT00403429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT04515979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib 300 mg BID and pembrolizumab 200 mg IV
Description: Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
Study NCT03131531 — intervention group
Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Study NCT03650218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THIODERM STRONG
Description: Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
Study NCT01224288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion CT scan
Description: DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
Study NCT03978689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
Study NCT03978689 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CUE-101
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
Study NCT03978689 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KEYTRUDA®, Pembrolizumab
Description: KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
Study NCT02528643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral capsule
Study NCT02528643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT02607176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heweizhixie capsule
Description: 3 #, Tid, Oral for 3 days
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Sabin-IPV
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose adjuvanted Sabin-IPV
Study NCT04136769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visceral Debranching
Description: Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
Study NCT01194076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-day intensive treatment
Description: Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
Study NCT00345865 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: irradiation therapy
Description: Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* > 1000 cGy to whole lung, kidney, or abdominal bath.~* > 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* > 3600 cGy to whole brain.
Study NCT00345865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.
Study NCT00345865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose Sabin-IPV
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose adjuvanted Sabin-IPV
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental fatiguing task
Description: a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mental fatiguing task
Description: a 30-minute computerized Stroop test will be used to induce mental fatigue before exercise intervention
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 45 - minute simulated soccer game
Description: an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 45 - minute simulated soccer game
Description: an intermittent running protocol using intensities and speeds seen in soccer will be used to simulate the physiological demands of the sport
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive function
Description: The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
Study NCT04576026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive function
Description: The Stroop test and a complex reaction time test will be used to assess cognitive function during exercise.
Study NCT01311609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane
Description: Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]
Study NCT01561521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKF-1
Description: 1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Sabin-IPV
Study NCT01709071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose adjuvanted Sabin-IPV
Study NCT02639481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
Study NCT03420729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
Study NCT03420729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastroscopy
Description: a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
Study NCT03420729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic assisted capsule endoscopy
Description: The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
Study NCT03420729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic assisted capsule endoscopy
Description: The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
Study NCT04523909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trajectory of neuroinflammatory proteins in CSF and blood
Description: Kinetics of neuroinflammatory markers in CSF and blood
Study NCT00079235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00079235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03843333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance
Description: TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
Study NCT03843333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
Study NCT03843333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resource Navigation
Description: CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
Study NCT03843333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
Study NCT02714998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: single dose systemic methotrexate administration (50 mg/m2)
Study NCT02714998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: salpingectomy
Description: Laparoscopic unilateral salpingectomy
Study NCT05819177 — intervention group
Intervention type: OTHER
Intervention: Rehabilitation program
Description: This group of patients underwent standard rehabilitation programs set by national guidelines.
Study NCT02147652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music
Study NCT01628263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up Clinic for High risk participants
Description: Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
Study NCT00582855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Study NCT00582855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01835847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipepidine Hibenzate
Study NCT01123356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: * Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles
Study NCT01123356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: -Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
Study NCT02639481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erigo®Pro group without FES
Description: Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
Study NCT02639481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erigo®Pro group with FES
Description: Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
Study NCT01143090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: 40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
Study NCT02183961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restech
Study NCT02183961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peptest
Study NCT02183961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of pepsin in adenoid specimen
Study NCT02697162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiseptic-coated catheter
Description: Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
Study NCT02697162 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrophilic catheter
Description: Hydrophilic intermittent urinary catheter
Study NCT02697162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidine chloride
Description: Antiseptic
Study NCT02023151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Study NCT01839032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine cisplatin radiotherapy
Description: During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy).
Study NCT02670161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Description: brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
Study NCT01561521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKF-1
Description: 1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
Study NCT02802332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Footlength Card
Description: The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
Study NCT00142532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture and Questionnaires
Description: Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory
Study NCT00142532 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture, Questionnaires
Description: The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other.
Study NCT01864980 — intervention group
Intervention type: PROCEDURE
Intervention: blood transfusion, intermittent Hbsatlab measurement
Description: In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
Study NCT01864980 — intervention group
Intervention type: PROCEDURE
Intervention: blood transfusion, based on continuous SpHb readings
Description: RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
Study NCT02181881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DuoPACT
Description: Intervention sessions are administered weekly by a counselor.
Study NCT02181881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Steps
Description: Intervention sessions are administered weekly by a counselor.
Study NCT03855384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Description: TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
Study NCT03855384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
Description: placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
Study NCT03077503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
Study NCT03077503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
Study NCT03077503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline
Description: 0.9% normal saline was use to dilute the study drugs
Study NCT03077503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: 0.9% normal saline was use to dilute the study drugs
Study NCT03077503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skull pins
Description: Skull pins were use to stabilized the patent' s head during surgery